Impact of Modifying Lazertinib Doses on Effectiveness and Safety in Patients With EGFR ‐Positive Advanced Lung Cancer: A Multicenter, Prospective Observational Cohort Study
Thoracic Cancer · 2025
DOI: 10.1111/1759-7714.70083 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Thoracic Cancer, 2025. Verfasst von Mi-Hyun Kim und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine, Pusan National University School of Medicine, Busan, Republic of Korea. Hauptthemen laut MEDLINE: Lung Neoplasms, Carcinoma, Non-Small-Cell Lung, Protein Kinase Inhibitors. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 10 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Yuhan.
Abstract (Originalsprache)
Introduction
The clinical application of lazertinib, a third‐generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, has extended to the treatment of EGFR‐mutant non‐small‐cell lung cancer (NSCLC); however, the effects of its dose modification on its efficacy and safety have not yet been adequately established.
Methods
This prospective, multicenter, observational cohort study aims to evaluate the clinical implications of adjusting the lazertinib dose. Patients will be categorized into two groups based on the lazertinib dose administered during the initial 12 weeks of treatment in routine clinical practice: 160 and 240 mg groups. The primary endpoints are progression‐free survival in the 160 mg group and identifying risk factors associated with dose modification during the 12‐week period.
Discussion
The findings from the present study will provide real‐world insights into the clinical factors leading to lazertinib dose adjustments and deepen our understanding of the efficacy and safety of lazertinib in patients with NSCLC. Our research will contribute toward optimizing medical strategies for NSCLC treatment and aid clinicians in making accurate clinical decisions regarding dose modifications in routine practice.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Internal Medicine, Pusan National University School of Medicine, Busan, Republic of Korea.
- Department of Internal Medicine, School of Medicine, Kyungpook National University, Daegu, Republic of Korea.
- Division of Pulmonology, Respiratory Center, Keimyung University Dongsan Hospital, Keimyung University School of Medicine, Daegu, Republic of Korea.
- Department of Internal Medicine, Kosin University Medical College, Busan, Republic of Korea.
- Department of Internal Medicine, Catholic University of Daegu School of Medicine, Daegu, Republic of Korea.
- Department of Internal Medicine, College of Medicine, Dong-A University, Busan, Republic of Korea.
ORCID-Profile: Mi-Hyun Kim, Sun Hyo Park, Insu Kim, June Hong Ahn, Jung Seop Eom
Förderung
- Yuhan
Zitieren
APA
Kim, M. H., Lee, M. K., Park, J. E., Park, S. H., Jang, T. W., Jung, C. Y., Kim, I., Yoon, S. H., Ahn, J. H., Lee, H. K., Park, J. H., Choi, S. H., & Eom, J. S. (2025). Impact of Modifying Lazertinib Doses on Effectiveness and Safety in Patients With EGFR ‐Positive Advanced Lung Cancer: A Multicenter, Prospective Observational Cohort Study. Thoracic Cancer. https://doi.org/10.1111/1759-7714.70083
Vancouver
Kim MH, Lee MK, Park JE, Park SH, Jang TW, Jung CY, et al. Impact of Modifying Lazertinib Doses on Effectiveness and Safety in Patients With EGFR ‐Positive Advanced Lung Cancer: A Multicenter, Prospective Observational Cohort Study. Thoracic Cancer. 2025. doi:10.1111/1759-7714.70083
BibTeX
@article{Kim2025,
author = {Kim, Mi-Hyun and Lee, Min Ki and Park, Ji Eun and Park, Sun Hyo and Jang, Tae Won and Jung, Chi Young and Kim, Insu and Yoon, Seong Hoon and Ahn, June Hong and Lee, Hyun-Kyung and Park, Jin Han and Choi, Sun Ha and Eom, Jung Seop},
title = {Impact of Modifying Lazertinib Doses on Effectiveness and Safety in Patients With EGFR ‐Positive Advanced Lung Cancer: A Multicenter, Prospective Observational Cohort Study},
journal = {Thoracic Cancer},
year = {2025},
doi = {10.1111/1759-7714.70083}
}
EUVIMED